E. Boleti - Sch Med, Acad Oncol Dept

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 28 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Outcome of Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab and the Primary Tumour in Place

L. Jurascheck, Fransen E. Van de Putte,L. Van den Brink,J. C. Van der Mijn,S. Wilgenhof,J. V. Van Thienen,J. B. A. G. Haanen,E. Boleti,T. Powles,P. J. Zondervan,N. M. Graafland,A. Bex

EUROPEAN UROLOGY (2024): S1859-S1860

引用0浏览0引用

LBA75 Prospective Randomised Phase-Ii Trial of Ipilimumab/nivolumab Versus Standard of Care in Non-Clear Cell Renal Cell Cancer: Results of the SUNNIFORECAST Trial

L. Bergmann, M. Ahrens, L. Albiges,M. Gross Goupil,E. Boleti, G. Gravis, A. Flechon,M-O.J. Grimm, S. Rausch, P. Barthelemy,D.E. Castellano Gauna,B. Mellado Gonzalez, P. Ivanyi,A. Floercken,C. Suarez Rodriguez,J.P. Maroto Rey, V. Gruenwald,I. Burkholder, A. Hartmann, J.B.A.G. Haanen

Annals of Oncology (2024)

引用0浏览0引用

Deferred Cytoreductive Nephrectomy Following Response to Ipilimumab/nivolumab, is There Potential for a Treatment-Free Interval

Fransen E. E. van de Putte,L. Van den Brink,M. Mansour,J. C. Van der Mijn,S. Wilgenhof,J. V. Van Thienen, J. B. A. Haanen,E. Boleti,T. Powles,P. J. Zondervan,N. M. Graafland,A. Bex

European Urology (2023): S475-S476

引用0浏览0引用

1906P Metastasized Non-Clear Cell Renal Cell Carcinoma: Which Entities Are Dangerous? Results Learned from Reference Pathology of the SuniForecast Study

A. Hartmann, L. Vorfelder,M. Ahrens,J. B. A. G. Haanen,B. Escudier,A. Ravaud,E. Boleti,G. Gravis,A. Flechon,M-O. Grimm,J. Bedke,B. Mellado Gonzalez,P. Ivanyi,I. Polifka, F. Lange,A. Agaimy,L. Bergmann,C. G. Stoehr

Annals of oncology (2023): S1026-S1026

引用0浏览0引用

PD-L1 expression in different non-clear cell renal cell carcinoma subtypes: an analysis of the SUNNIFORECAST cohort

ONCOLOGY RESEARCH AND TREATMENT (2023): 77-78

引用0浏览0引用

Surgical Safety of Cytoreductive Nephrectomy (CN) Following Pretreatment with Immune Checkpoint Inhibition (ICI) Combination Therapy in Primary Metastatic Clear-Cell Renal Carcinoma (Mccrcc)

N. M. Graafland,B. Szabados,F. Mumtaz,R. Barod,D. Nicol,C. Tanabalan,E. Boleti,T. Powles,J. Haanen,A. Bex

European Urology（2021）

引用0浏览0引用

737P Synchronous Metastatic Renal Cell Carcinoma (mrcc) Treated with Nivolumab and Ipilimumab (N+I) and the Primary Tumour (PT) in Place

A. Meerveld-Eggink,N. Graafland,S. Wilgenhof,J. V. Van Thienen,M. Grant,B. E. Szabados,Y. Abu-Ghanem,E. Boleti,C. U. Blank,J. B. A. G. Haanen,T. B. Powles,A. Bex

Annals of Oncology（2020）

引用2浏览0引用

Cabozantinib in Metastatic Renal Cell Carcinoma (mrcc): Data from UK Expanded Access Program (EAP)

A. Gomez de Liano Lista,B. Venugopal,K. Fife,S. Symeonides,N. S. Vasudev,S. M. Rudman, S. Vohra, L. Khasati, C. Pettinger,B. Szabados,L. Morrison,T. Powles,E. Boleti

Annals of Oncology（2018）

引用3浏览0WOS引用

SUNNIFORECAST - A Phase II Study of Nivolumab in Combination with Ipilimumab Versus Standard of Care in Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

S. Scheich,M. Ahrens,N. Goekbuget,E. Boleti,I Burkholder,B. J. Escudier,P. J. Goebell,V Gruenwald,J. Gschwend,M. Retz,A. Hartmann,J. P. Maroto Rey, K. Miller,M. -O Grimm,S. Siemer,A. Panic,L. Bergmann

ONCOLOGY RESEARCH AND TREATMENT（2018）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn